Navigation Links
Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
Date:4/24/2008

SANTA MONICA, Calif., April 24 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that it has completed the acquisition of a controlling interest in Jiangsu Institute of Microbiology Co., Ltd. ("JSIM"), one of the leading microbiology research institutes in the People's Republic of China. JSIM has several drugs currently undergoing clinical testing and has new products in its development pipeline. This acquisition is expected to add several new products to Aida Pharmaceutical Inc.'s existing line of products, thus diversifying its product mix and enabling the Company to increase its market share in the PRC pharmaceutical market.

The controlling interest in JSIM was acquired through two of Aida Pharmaceutical Inc.'s subsidiaries, namely Hangzhou Aida Pharmaceutical Co., Ltd. (which acquired a 43% equity interest) and Changzhou Fangyuan Pharmaceutical Co., Ltd. (which acquired a 55% equity interest).

JSIM is a national leader in microbiology with over thirty years of research history. It is located in Wuxi City in Jiangsu Province, has over thirty scientists and engineers that have completed over 200 research projects. Of these research projects, over twenty of them were developed as national-level key projects, as designated by the Chinese government. JSIM's research efforts have yielded numerous patents.

About Aida Pharmaceuticals, Inc.

Aida Pharmaceuticals, Inc. is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, Inc., in operation since March 1999, is headquartered in Hangzhou, People's Republic of China with manufacturing, distribution and sales points throughout mainland China. Aida Pharmaceuticals, Inc.
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
2. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
3. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
4. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
5. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
6. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
9. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
10. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email: